Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros and NIH amend license agreement for Proellex

July 10, 2009

Novel inhibitor may allow physiological understanding of fatty acid elongase 6

July 9, 2009

Hameln rds describes novel ACAT inhibitors for the treatment of lipoprotein disorders

July 9, 2009

Shire files treatment protocol with FDA for velaglucerase alfa for Gaucher disease

July 9, 2009

Bayer submits NDA to FDA for oral contraceptive estradiol valerate/dienogest

July 9, 2009

Kuros initiates treatment in phase IIb clinical trial of KUR-211 in diabetic foot ulcers

July 9, 2009

FDA approves Hyperion's SPA for phase III clinical trial of HPN-100 in adults with UCD

July 9, 2009

Repros provides update on clinical development of Proellex

July 8, 2009

Bar-Ilan University patent describes novel P2Y1 receptor agonists

July 7, 2009

Action Pharma discovers and patents novel melanocortin receptor ligands

July 7, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...